• 1

    Ottesen EA, Ismail MM, Horton J, 1999. The role of albendazole in programmes to eliminate lymphatic filariasis. Parasitol Today 15 :382–386.

    • Search Google Scholar
    • Export Citation
  • 2

    Pani SP, Redy GS, Das LK, Vanamail P, Hoti SL, Ramesh J, Das PK, 2002. Tolerability and efficacy of single dose albendazole, diethylcarbamazxine citrate (DEC) or co-administration of albendazole with DEC in the clearance of Wucheria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, south India: a hospital-base study. Filaria J 1 :1–11.

    • Search Google Scholar
    • Export Citation
  • 3

    Dunyo SK, Nkrumah FK, Simonsen PE, 2000. Single-dose treatment of Wuchereria bancrofti infections with ivermectin and albendazole alone or in combination: evaluation of the potential for control at 12 months after treatment. Trans R Soc Trop Med Hyg 94 :437–443.

    • Search Google Scholar
    • Export Citation
  • 4

    Sarin R, Dash AP, Dua VK, 2004. Albendazole sulphoxide concentrations in plasma of endemic normals from a lymphatic filariasis endemic region using liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 799 :233–238.

    • Search Google Scholar
    • Export Citation
  • 5

    Sahoo PK, Geddam JJB, Satapathy AK, Mohanty MC, Ravindran B, 2000. Bancroftian filariasis: prevalence of antigenaemia and endemic normals in Orissa, India. Trans R Soc Trop Med Hyg 94 :515–517.

    • Search Google Scholar
    • Export Citation
  • 6

    Zeger SL, Liang KY, 1986. The analysis of discrete and continuous longitudinal data. Biometrics 42 :121–130.

  • 7

    Liang KY, Zeger SL, 1986. Longitudinal data analysis using generalized linear models. Biometrika 73 :13–22.

  • 8

    Pinheiro JC, Bates DM, 2000. Mixed-Effects Models in S and S-plus. New York: Springer.

  • 9

    Anderson RM, May RM, 1992. Infectious Diseases of Humans. Dynamics and Control. Oxford, United Kingdom: Oxford University Press.

  • 10

    International Filariasis Review Group, (Addiss D, Critchley J, Ejere H, Garner P, Gelband H, Gamble C, 2004. Albendazole for lymphatic filariasis (Cochrane Review). The Cochrane Library, Issue 1. Chichester, United Kingdom: John Wiley & Sons, Ltd.

  • 11

    Collet D, 1991. Modelling Binary Data. London: Chapman & Hall.






View More View Less
  • 1 Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar, India; Department of Infectious Disease Epidemiology, Imperial College of Medicine, London, United Kingdom

Subjects in an disease-endemic area in Orissa, India concomitantly infected with filariasis and intestinal helminths had significantly lower intensity of filarial infection in comparison with those who were infected only with filariasis. Administration of albendazole resulted in a significant decrease in the prevalence of filarial antigenemia in subjects concomitantly infected with intestinal helminths, but produced little change in this infection measure in subjects infected only with Wuchereria bancrofti. These results indicate that intestinal helminths could play a role in the anti-filarial activity of albendazole, most probably by depressing filarial infection intensity in co-infected individuals. Confirmation of these findings in a larger cohort may yield important new insights regarding the role of using albendazole in the ongoing intervention programs for the control of lymphatic filariasis.

Author Notes

Reprint requests: Balachandran Ravindran, Division of Immunology, Regional Medical Research Centre, Indian Council of Medical Research, Bhubaneswar 751023, India.